Regeneron Pharmaceuticals Files 8-K on Security Holder Votes

TL;DR

Regeneron filed an 8-K on June 20th about shareholder votes from June 14th.

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on June 20, 2024, reporting on matters submitted to a vote of security holders on June 14, 2024. The filing details the company's principal executive offices located at 777 Old Saw Mill River Road, Tarrytown, New York.

Why It Matters

This filing provides transparency regarding decisions made by Regeneron's security holders, which can impact corporate governance and future strategic directions.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of corporate actions and does not indicate any immediate financial or operational risks.

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — Registrant
• June 20, 2024 (date) — Date of Report
• June 14, 2024 (date) — Date of earliest event reported
• 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select M

Filing Documents

• tm2417559d1_8k.htm (8-K) — 41KB
• 0001104659-24-073372.txt ( ) — 210KB
• regn-20240614.xsd (EX-101.SCH) — 3KB
• regn-20240614_lab.xml (EX-101.LAB) — 33KB
• regn-20240614_pre.xml (EX-101.PRE) — 22KB
• tm2417559d1_8k_htm.xml (XML) — 4KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. At the 2024 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (" Regeneron " or the " Company ") held on June 14, 2024, Regeneron's shareholders voted on the matters set forth below. Proposal 1 – Election of Directors The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: Nominee For Against Abstain Broker Non-Votes N. Anthony Coles, M.D. 110,481,731 1,873,397 99,413 4,213,730 Kathryn Guarini, Ph.D. 111,988,738 359,659 106,144 4,213,730 Arthur F. Ryan 81,009,658 31,288,101 156,782 4,213,730 George L. Sing 102,751,205 9,574,839 128,497 4,213,730 The following nominee for Class II director was elected to serve until the 2026 Annual Meeting of Shareholders and until his successor is duly elected and qualified based upon the following votes: Nominee For Against Abstain Broker Non-Votes David P. Schenkein, M.D. 106,839,998 5,501,139 113,404 4,213,730 Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved based upon the following votes: For: 111,350,016 Against: 5,257,636 Abstain: 60,619 Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 25, 2024 was approved based on the following votes: For: 106,667,264 Against: 5,579,814 Abstain: 207,463 Broker Non-Votes: 4,213,730 Proposal 4 – Non-Binding Shareholder Proposal Requesting Simple Majority Voting Requirements

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REGENERON PHARMACEUTICALS, INC. /s/ Joseph J. LaRosa Joseph J. LaRosa Executive Vice President, General Counsel and Secretary Date: June 20, 2024

View Full Filing

View this 8-K filing on SEC EDGAR